ACTUHealthcare · BiotechnologyACTU Stock Forecast: Actuate Therapeutics, Inc. Price Predictions for 2026-2027
The 4 Wall Street analysts covering Actuate Therapeutics, Inc. hold a median 12-month price target of $10 — +687.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
ACTU stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Actuate Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (86): Smaller than most of the companies we track.
Quality (12): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
ACTU stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ACTU, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +687.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $15 |
| 30 July 2026 | Rodman & Renshaw | Initiates | Buy | $6.00 |
| 30 July 2026 | Rodman & Renshaw | Initiates | Buy | — |
| 18 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $15 |
| 18 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Nov 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 23 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Aug 2025 | B. Riley Securities | Initiates | Buy | — |
| 18 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Mar 2025 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACTU appears on the weeks it earns a place.
ACTU analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Actuate Therapeutics, Inc. (ACTU) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 6.8×
- Price / sales
- —
- Price / book
- 31.0×
- EV / EBITDA
- −1.2×
Cheaper than 64% of US stocks
Cheaper than 4% of US stocks
Cheaper than 67% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −280.5%
- Return on assets
- −213.4%
- Dividend yield
- —
Higher than 5% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ACTU vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Actuate Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about ACTU stock
What is the ACTU stock price forecast for 2026-2027?
The 4 Wall Street analysts covering Actuate Therapeutics, Inc. have a median 12-month price target of $10, with estimates ranging from $5 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ACTU stock a buy right now?
Of the 4 analysts covering Actuate Therapeutics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Actuate Therapeutics, Inc. 27 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ACTU?
As at 22 Aug 2026, Actuate Therapeutics, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).
Will ACTU stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts implies +687.4% from the last close, and Ticker Nerd's factor model ranks Actuate Therapeutics, Inc. 27 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ACTU stock forecast for 2030?
No analyst covering Actuate Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACTU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $15 over the next 12 months.
How has ACTU stock performed over the past year?
Actuate Therapeutics, Inc. returned -83.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Actuate Therapeutics, Inc. do?
Actuate Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers through inhibition of glycogen synthase kinase-3, particularly the GSK-3β isoform.
About Actuate Therapeutics, Inc.
Actuate Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers through inhibition of glycogen synthase kinase-3, particularly the GSK-3β isoform. Its lead investigational drug, elraglusib, is a small-molecule inhibitor designed to block GSK-3β function within cancer cells, targeting key signaling pathways like NF-κB that promote tumor survival, growth, migration, invasion, and resistance to chemotherapy while enhancing anti-tumor immunity. Elraglusib is under evaluation in Phase 2 trials for metastatic pancreatic ductal adenocarcinoma, with Orphan Drug and Fast Track Designations, and in Phase 1/2 trials for refractory pediatric malignancies such as Ewing sarcoma and neuroblastoma, as well as metastatic melanoma and colorectal cancer. The company also pursues an oral formulation of elraglusib, completing Phase 1 in healthy volunteers and planning further studies in advanced cancers. Actuate Therapeutics Inc. operates in the biotechnology sector, addressing unmet needs in oncology for solid tumors and hematologic malignancies. Founded in 2015 and headquartered in Fort Worth, Texas, it maintains a strategic pipeline aimed at GSK-3β associated diseases.
CEO Mr. Daniel M. Schmitt · 12 employees · United States · https://actuatetherapeutics.com